Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > October 7, 2022
Daily News
October 7, 2022
- Moderna Probing Correlations between Spikevax Adverse Reactions and Immune Response: SVP
October 7, 2022
- Look at Drug Prices as Long-Term Investment, Not as Cost: EFPIA President
October 7, 2022
- EFPIA Chief Prods Japan on Mutual Trial Data Recognition, Cooperation to Boost Attractiveness to Rival US, China
October 7, 2022
- Opdivo Top-Selling Drug in Japan for 9 Consecutive Months: Encise
October 7, 2022
- Santen’s Glaucoma Drug Accepted for Review in Europe
October 7, 2022
- Fujifilm to Launch Domestic Bio-CDMO Site in FY2026 to Bolster Vaccine Production
October 7, 2022
- Sumitomo to Incur 54 Billion Yen in Impairment Loss on Kynmobi
October 7, 2022
- Towa’s Win in Livalo Damage Suit Now Final and Binding
October 7, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…